Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517
摘要:
Based on the lead compound BX-517, a series of C-4 ' substituted indolinones have been synthesized and evaluated for PDK1 inhibition. Modification at C-4 ' of the pyrrole afforded potent compounds (7b and 7d) with improved solubility and ADME properties. In this letter, we describe the synthesis, selectivity profile, and pharmacokinetic data of selected compounds. (C) 2007 Elsevier Ltd. All rights reserved.
Indolinone derivatives and their use in treating disease-states such as cancer
申请人:Arnaiz Damian
公开号:US20050090541A1
公开(公告)日:2005-04-28
Indolinone derivatives, such as compounds of the formula (I):
wherein A, m, n, R
1
, R
2
, R
3
, R
5
and R
6
are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity.
NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES
申请人:GALAPAGOS NV
公开号:US20160297830A1
公开(公告)日:2016-10-13
Compounds are disclosed that have a formula represented by the following:
wherein A, B, R
1
, R
2
and R
3
are as defined herein.
Novel compounds of the invention may be prepared as a pharmaceutical composition, and may be useful in the treatment of infectious diseases, in particular bacterial infectious diseases. The compounds may be active against a specific enzyme in the bacterial DNA replicative process, DNA polymerase IIIE.
The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).